We found that colorectal cancer (CRC) cell lines harboring KRAS and TP53 mutations, two of the most common mutations in PDA patients [20], were insensitive to GOT1 inhibition in vitro and in vivo. The gene discussed is KRAS; the disease is Patent ductus arteriosus.